article

Formulation In-Depth Focus 2019

As today’s scientists continue to identify new biopharmaceutical products with potential to treat a wide array of diseases, formulation remains the determining factor in their success. But what is involved in these increasingly complex formulation processes and how do they impact the packaging and delivery systems?











To read this In-Depth Focus in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Captisol, Cydex, Infectious Disease Research Institute, National Institutes of Health (NIH), Novartis, Saint Louis University School of Medicine

  • Ever more complex formulations and active biological products raise new challenges for pre-filled syringe development. In his article, James Mellman, Device Manager at Novartis, discusses the challenges of selecting the right primary packaging for injectable formulations and how he has learnt to expect the unexpected. 
  • Vaccinations have begun in a phase I human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine candidate. In an article by Nikki Withers we hear from Dr Daniel Hoft and Christopher Fox about the formulation process and what this means for vaccine development going forward.

 

Send this to a friend